/QLGN
QLGN Stock - Qualigen Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$3.21+5.59%
+$0.17 (+5.59%) • Nov 18
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.35
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $3.53
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for QLGN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.18 – $3.24
TARGET (TP)$3.69
STOP LOSS$2.95
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.28
52W High$8.81
52W Low$1.61
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $5.20M | $4.98M | $5.65M | $4.31M |
| Gross Profit | N/A | $-4,495 | $680,801 | $1.32M | $-2,879,641 |
| Gross Margin | N/A | -0.1% | 13.7% | 23.4% | -66.9% |
| Operating Income | $-5,761,720 | $-11,304,857 | $-17,942,399 | $-22,663,036 | $-12,679,522 |
| Net Income | $-6,159,191 | $-13,417,212 | $-21,034,643 | $-17,897,137 | $-20,418,942 |
| Net Margin | N/A | -257.8% | -422.1% | -316.6% | -474.2% |
| EPS | $-17.28 | $-2.46 | $-5.48 | $-6.10 | $-7.98 |
Company Overview
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
QLGNBeat Rate
50%
Last 12 quarters
Avg Surprise
-1403.6%
EPS vs Estimate
Beats / Misses
6/6
Last 12 quarters
Latest EPS
$-4.68
Q4 2025
EPS Surprise History
Q2 24
No data
Q2 24
+98.2%
$-0.47vs$-26.00
Q3 24
No data
Q4 24
No data
Q2 25
No data
Q3 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | — | $-4.68 | — | — |
Q3 2025 | Aug 16, 2025 | — | $-1.82 | — | — |
Q3 2025 | Jul 21, 2025 | — | $-1.82 | — | — |
Q2 2025 | Jun 30, 2025 | — | $-11621.22 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-4.70 | — | — |
Q3 2024 | Jul 2, 2024 | — | $-17.50 | — | — |
Q2 2024 | Jun 25, 2024 | $-26.00 | $-0.47 | +98.2% | ✓ BEAT |
Q2 2024 | Apr 30, 2024 | — | $-0.47 | — | — |
Q4 2023 | Nov 14, 2023 | $-46.00 | $-32.00 | +30.4% | ✓ BEAT |
Q3 2023 | Aug 15, 2023 | $-26.00 | $-34.50 | -32.7% | ✗ MISS |
Q2 2023 | May 16, 2023 | $-42.50 | $-39.00 | +8.2% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-1.40 | $-1.50 | -7.1% | ✗ MISS |
Q4 2022 | Nov 15, 2022 | $-1.30 | $-50.00 | -3746.2% | ✗ MISS |
Q3 2022 | Aug 16, 2022 | $-90.00 | $-55.00 | +38.9% | ✓ BEAT |
Q2 2022 | May 13, 2022 | $-1.70 | $-70.00 | -4017.6% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-2.05 | $-75.00 | -3558.5% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-105.00 | $-50.00 | +52.4% | ✓ BEAT |
Q3 2021 | Aug 17, 2021 | — | $-90.00 | — | — |
Q2 2021 | May 14, 2021 | $-1.60 | $-105.00 | -6462.5% | ✗ MISS |
Q1 2021 | Mar 31, 2021 | $-1.30 | $8.50 | +753.8% | ✓ BEAT |
Latest News
AIxCrypto Renames From Qualigen To AIxCrypto Holdings; Begins Trading Under New Ticker AIXC
➖ NeutralBenzinga•Nov 20, 2025, 05:41 PM
Reported Earlier, Qualigen Therapeutics To Rebrand As AIxCrypto, Targets Three Strategic Milestones For 2025 Including $50M Crypto AUM
➖ NeutralBenzinga•Oct 28, 2025, 06:21 AM
Qualigen Therapeutics shares are trading higher after the company announced a strategic partnership with BitGo to support its C10 treasury strategy focused on top cryptocurrencies.
📈 PositiveBenzinga•Oct 24, 2025, 12:41 PM•Also:
Qualigen Therapeutics shares are trading higher after the company announced a strategic partnership with BitGo to support its C10 treasury strategy focused on top cryptocurrencies.
📈 PositiveBenzinga•Oct 23, 2025, 08:14 PM•Also:
Qualigen Therapeutics Enters Strategic Partnership With BitGo To Support Its C10 Treasury Strategy Focusing On Accumulating And Compounding A Market-Cap-Weighted Basket Of The World's Top 10 Cryptocurrencies, Excluding Stablecoins
📈 PositiveBenzinga•Oct 23, 2025, 08:12 PM•Also:
Reported Earlier, Qualigen Therapeutics Launches CXC10 Asset Purchases After Market Shakeout, Emphasizing Smart Investment Framework And Risk Management
📈 PositiveBenzinga•Oct 13, 2025, 06:22 AM
Reported Earlier, Qualigen Therapeutics Announces Major Leadership Overhaul, Appointing Jerry Wang Co-CEO And Koti Meka CFO
➖ NeutralBenzinga•Oct 7, 2025, 07:12 AM
Qualigen Therapeutics Closes $41M Private Investment In Public Equity Financing
📈 PositiveBenzinga•Sep 30, 2025, 11:11 AM
Faraday Future Secures Majority Stake In Qualigen Therapeutics With $41M Investment As QLGN Prepares To Rebrand As CXC10 For Web3 Shift
📈 PositiveBenzinga•Sep 30, 2025, 10:06 AM•Also:
Qualigen Therapeutics shares are trading higher after Faraday Future announced a $41 million investment in the company.
📈 PositiveBenzinga•Sep 22, 2025, 01:28 PM•Also:
Market-Moving News for September 22nd
➖ NeutralBenzinga•Sep 22, 2025, 11:26 AM•Also: ,
Faraday Future Announces Strategic $41M Investment In Qualigen Therapeutics For Crypto Business Through Pipe Transaction; At Deal Close, YT Jia To Be Chief Advisor, Jerry Wang Co-CEO, Koti Meka CFO Of QLGN; On Completion, Co And YT Jia To Own Over 62% Of QLGN; Co To Invest $30M In QLGN, Co-CEO YT Jia Investing $4M
📈 PositiveBenzinga•Sep 19, 2025, 10:10 PM•Also:
Reported On September 16th: Qualigen Therapeutics Files To Sell Up To 3.21M Shares Of Common Stock For Holders
📉 NegativeBenzinga•Sep 17, 2025, 04:14 PM
Frequently Asked Questions about QLGN
What is QLGN's current stock price?
Qualigen Therapeutics, Inc. (QLGN) is currently trading at $3.21 per share. The stock has moved +5.59% today.
What is the analyst price target for QLGN?
No analyst price targets are currently available for this stock.
What sector is Qualigen Therapeutics, Inc. in?
Qualigen Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is QLGN's market cap?
Qualigen Therapeutics, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does QLGN pay dividends?
No, Qualigen Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCANF
Can-Fite BioPharma Ltd.
$0.25
Mkt Cap: $0.0B
CMND
Clearmind Medicine Inc.
$2.74
Mkt Cap: $0.0B
CNSP
CNS Pharmaceuticals, Inc.
$6.51
Mkt Cap: $0.0B
ENSC
Ensysce Biosciences, Inc.
$1.16
Mkt Cap: $0.0B
KALA
KALA BIO, Inc.
$0.62
Mkt Cap: $0.0B
KZIA
Kazia Therapeutics Limited
$10.87
Mkt Cap: $0.0B
OGEN
Oragenics, Inc.
$0.88
Mkt Cap: $0.0B
SNGX
Soligenix, Inc.
$1.38
Mkt Cap: $0.0B
TTNP
Titan Pharmaceuticals, Inc.
$2.34
Mkt Cap: $0.0B
XBIO
Xenetic Biosciences, Inc.
$2.15
Mkt Cap: $0.0B
Explore stocks similar to QLGN for comparison